tender for coronary drug eluting stents, srphc82281225-coronary drug eluting stents with (1) cobalt chromium allo y (2) coating of bioabsorbable polymer carrier with abluminal and gradient coating for active drug shown to be effective in preventing neo-intimal hyperplasia) (3) stent diamet er should be from 2.5mm to 4mm . the length of the stent should be from 12mm to 38 mm . (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) th e long term efficacy and safety of the stent, the rates of in-stent restenosis (isr) and i n-situ thrombosis (ist) should be documented / published in peer reviewed scientific jour nals. (10) safety of abbreviated (one month) dual antiplatelet therapy for high bleeding risk patients should be documented in peer reviewed journals. (11) the manufacturer/su pplier should submit proof of supply of the stent to a major government institute. bis s tandards for the drug eluting stent are not available. (reference:bis catalogue ). -quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitt ed: max 8 lacs

Latest Tender Detail from southern railway SR for the tender for coronary drug eluting stents, srphc82281225-coronary drug eluting stents with (1) cobalt chromium allo y (2) coating of bioabsorbable polymer carrier with abluminal and gradient coating for active drug shown to be effective in preventing neo-intimal hyperplasia) (3) stent diamet er should be from 2.5mm to 4mm . the length of the stent should be from 12mm to 38 mm . (4) the strut thickness should be 91 micron or less. (5) stent delivery system should be monorail (single operator exchange or rapid exchange). (6) stent should be compatible with 5fr guiding catheter (7) stent design should be open cell type. (8) stent should be approved by dcgi. the copy of dcgi approval should be enclosed in the tender bid. (9) th e long term efficacy and safety of the stent, the rates of in-stent restenosis (isr) and i n-situ thrombosis (ist) should be documented / published in peer reviewed scientific jour nals. (10) safety of abbreviated (one month) dual antiplatelet therapy for high bleeding risk patients should be documented in peer reviewed journals. (11) the manufacturer/su pplier should submit proof of supply of the stent to a major government institute. bis s tandards for the drug eluting stent are not available. (reference:bis catalogue ). -quantity tolerance (+/-): 5 %age , item category : normal , total po value variation permitt ed: max 8 lacs in perambalur, tamil nadu,. Reference number 15392235. Don't miss out on this chance to be part of a significant project. Register for free today to access the complete tender details and download the necessary documents. Seize the opportunity with Tender 18!